JHL Biotech opens new biosimilar manufacturing facility in China

May 11, 2016 8:26 AM


JHL Biotech (JHL) opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China.

JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars and monoclonal antibodies (mAbs) for late–stage clinical trials and commercial supply. The facility will also provide process development and manufacturing services for JHL’s global customer base.

JHL and GE Healthcare partnered to complete the construction of the facility in just 18 months using GE’s KUBio manufacturing solution. KUBio is a prefabricated cGMP-compliant facility and process solution designed for scalable and cost-efficient manufacturing.

The biosimilars market is expected to grow significantly in China, reaching approximately USD 350 million in 2019, up from USD 44 million in 2009. Local manufacturing in China is a more affordable way to provide modern therapies for deadly diseases like cancer, which is the leading cause of death in China. In 2015, approximately 4.3 million new cancer cases were reported in the country. China’s State Council’s 10-year action plan “Made in China 2025” recognizes biological medicines and medical devices as one of its key industrial focus areas.

Racho Jordanov, CEO and co-founder of JHL Biotech commented, “JHL Biotech’s mission is to make quality medicines affordable to more people, and we believe one of the greatest areas of need is in Asia. It was important to us to establish our scale-up manufacturing capacity in Asia with a manufacturing facility in China capable of producing biologics to a world-class standard. JHL’s new facility in Wuhan has the same standardized GE FlexFactoryTM technology as our existing site in Taiwan, which allowed us to quickly scale up to a capacity of 2,000 litres. JHL Biotech now has the largest volume of single-use cell culture capacity in Asia with the opening of our new facility in Wuhan.”

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!